2,2,3,3-四氟-6-氨基苯并烷 | 89586-07-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 中文名称: 2,2,3,3-四氟-6-氨基苯并烷
• 中文别名: 6-氨基-2,2,3,3-四氟-1,4-苯基二噁烷；2,2,3,3-四氟-6-氨基苯并二氧烯
• 英文名称: 2,2,3,3-tetrafluoro-2,3-dihydrobenzo[1,4]dioxin-6-ylamine
• 英文别名: 2,2,3,3-tetrafluoro-6-amino-1,4-benzodioxine；2,2,3,3-tetrafluoro-6-amino-2,3-dihydrobenzo[1,4]dioxine；6-amino-2,2,3,3-tetrafluoro-1,4-benzodioxene；2,2,3,3-tetrafluoro-2,3-dihydro-benzo[1,4]dioxin-6-ylamine；2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-amine；2,2,3,3-tetrafluoro-6-amino-1,4-benzodioxene；2,2,3,3-Tetrafluoro-2,3-dihydrobenzo[b][1,4]dioxin-6-amine；2,2,3,3-tetrafluoro-1,4-benzodioxin-6-amine
• CAS: 89586-07-2
• 化学式: C₈H₅F₄NO₂
• mdl: MFCD00190146
• 分子量: 223.127
• InChiKey: DCMDRNWAGHTMTR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  7

安全信息

• 危险品标志：
  T
• 安全说明：
  S36/37/39,S45
• 危险类别码：
  R20/21/22
• 危险品运输编号：
  2811

反应信息

• 作为反应物：
  描述：

  2,2,3,3-四氟-6-氨基苯并烷 生成 2,2,3,3-四氟-6-羟基苯
  参考文献：
  名称：

  SIRRENBERG, W.;MARHOLD, A.;BECKER, B.

  摘要：

  DOI：
• 作为产物：
  描述：

  2,2,3,3-tetrafluoro-6-nitro-2,3-dihydrobenzo[b][1,4]dioxane 生成 2,2,3,3-四氟-6-氨基苯并烷
  参考文献：
  名称：

  MARHOLD, A.;SIRRENBERG, W.;KLAUKE, E.;HAMMANN, I.;BECKER, B.;KREHAN, I.;S+

  摘要：

  DOI：

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Pyrazole compounds
  申请人：——

  公开号：US20030060453A1

  公开（公告）日：2003-03-27

  Pharmaceutical compositions and compounds are provided. The compounds of the invention demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, pharmaceutical compositions of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical compositions are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are substituted pyrazoles and pyrazolines.

  提供药物组合物和化合物。发明的化合物显示出抗增殖活性，并且可能促进缺乏正常细胞周期和死亡调控的细胞的凋亡。发明的一个实施例提供了化合物与生理可接受载体组合的药物组合物。该药物组合物可用于治疗过度增殖障碍，包括肿瘤生长、淋巴增殖性疾病、血管生成。发明的化合物是取代吡唑和吡唑啉。
• Novel amides useful for treating pain
  申请人：Zheng Zhu Guo

  公开号：US20050080095A1

  公开（公告）日：2005-04-14

  The present invention relates to compounds of formula (I-VII) or a pharmaceutically acceptable salt or prodrug thereof, in which A, L, R 6 , R 7 and R 8 are defined herein. The present invention also relates to methods of trating pain using these compounds and pharmaceutical compositions including these compounds.

  本发明涉及式(I-VII)的化合物或其药用可接受的盐或前药，其中A、L、R6、R7和R8在此有所定义。本发明还涉及使用这些化合物治疗疼痛的方法以及包含这些化合物的药物组合物。
• 2,4-Pyrimidinediamine Compounds and Their Uses
  申请人：Singh Rajinder

  公开号：US20150266828A1

  公开（公告）日：2015-09-24

  The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

  本发明提供了抑制IgE和/或IgG受体信号级联反应的2,4-嘧啶二胺化合物，该级联反应导致化学介质的释放，以及合成这些化合物的中介体和方法，以及在多种情况下使用这些化合物的方法，包括在治疗和预防由脱粒和其他由IgE和/或IgG受体信号级联反应激活引起的化学介质释放所表征、引起或相关的疾病。